drugset / Trial / NCT03914768
Immune Modulatory DC Vaccine Against Brain Tumor
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generated by autologous dendritic cells (DCs) pulsed with genetically modified tumor cells or tumor-related antigens including neoantigens to inject into patients. Vaccine-induced T cell responses have been associated with improved survival. The study will evaluate the safety and potential benefit of the novel immunomodulatory DC vaccines.
Timeline
- Start
- 2026-05-31
- Primary completion
- 2029-05-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immunomodulatory DC vaccine | Vaccine | 5e+06 cells | Other |
| Subject | Immunomodulatory DC vaccine | Vaccine | 1e+07 cells | Other |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 200 mg/m2 | Intravenous |